HB26-1325 expands Colorado’s natural medicine framework to include ibogaine and creates a state-run ibogaine research pilot program within the Behavioral Health Administration (BHA). The bill’s stated purpose is to study the safety and effectiveness of ibogaine for treating mental health conditions and substance use disorders, with an emphasis on medically supervised use, federal compliance, data collection, and eventual development of a broader regulatory structure. The BHA may authorize up to five pilot sites, establish a review committee to evaluate applications, seek federal approvals and research status, and coordinate with federal agencies, other states, tribes, and private entities. The bill also directs the BHA to pursue grants and donations, create a dedicated cash fund, and report pilot findings on its website.
In addition to the pilot program, the bill amends Colorado’s natural medicine statutes to treat ibogaine, including certain semi-synthetic forms, as a natural medicine subject to regulation by the state licensing authority. It authorizes rulemaking on ibogaine administration, including medical prescreening, continuous monitoring, trained oversight, and aftercare. The bill also changes the composition and appointment criteria for the natural medicine advisory board so that all 15 voting members must have relevant expertise tied to the natural medicine being considered, and it directs the board to prioritize ibogaine when recommending additional natural medicines for regulation. It further adjusts licensing rules, including priority review for applicants participating in the ibogaine pilot, the ability to set different fees by substance type, and requirements for benefit-sharing plans with Indigenous communities for ibogaine-related licensing and research.
The bill also creates liability protections for facilitators and health professionals involved in natural medicine services and ibogaine pilot activities, limiting malpractice damages unless injury results from intentional misconduct, gross negligence, or deviation from accepted standards of care. It conditions the pilot program’s operation on federal approval and includes a funding trigger: key provisions take effect only if the BHA receives at least $150,000 in gifts, grants, donations, or in-kind support before January 1, 2028, and the program is repealed if sufficient additional funding is not secured within a year. Any remaining money in the pilot fund may be transferred to the regulated natural medicine cash fund.
The general sentiment reflected in the bill text is strongly supportive of ibogaine research and cautious about implementation. The legislative declaration frames the measure as a response to Colorado’s mental health and substance use crisis, highlights potential benefits for veterans and people with severe disorders, and emphasizes a carefully regulated, medically supervised approach. The bill’s structure suggests an effort to balance innovation with oversight, federal compliance, and patient safety.
The main points of contention likely center on ibogaine’s status as a Schedule I substance, the adequacy of the safety evidence, and the bill’s use of liability protections and conditional funding to launch a pilot program before broader regulatory acceptance. Another notable issue is the bill’s requirement for benefit-sharing with Indigenous communities and documentation of sourcing, which indicates sensitivity to traditional knowledge and ethical sourcing but may also raise questions about implementation. No committee transcript or vote record was provided, so the bill’s support or opposition in discussion and voting cannot be assessed beyond the text itself.
The bill amends multiple sections of Colorado law governing natural medicine, including definitions, board composition, licensing priorities, rulemaking authority, cash funds, and civil liability protections. It adds ibogaine to the state’s natural medicine framework, authorizes the BHA to run a limited research pilot program, and creates a new ibogaine research pilot program cash fund while also allowing gifts, grants, and donations to support both the pilot and the broader regulated natural medicine system. It also requires the state licensing authority and advisory board to adopt ibogaine-specific rules and to consider ibogaine when expanding the list of regulated natural medicines.
The bill appears generally favorable toward expanding access to and research on ibogaine, with supporters framing it as a response to Colorado’s mental health and substance use crisis and as a way to explore a promising treatment under controlled conditions. The text emphasizes safety, federal authorization, and data-driven oversight, suggesting an intent to present the measure as a cautious pilot rather than immediate broad legalization. No vote history or committee testimony was provided, so there is no direct record here of opposition or support from legislators or stakeholders.
Likely areas of contention include ibogaine’s legal status under federal law, the sufficiency of evidence supporting its safety and effectiveness, and whether the state should create liability protections for providers involved in a pilot program. The bill’s reliance on private or public donations and a funding threshold before implementation may also be debated as a practical or political limitation. Additional sensitivity may arise around the bill’s benefit-sharing requirements with Indigenous communities, the sourcing of ibogaine, and the decision to prioritize ibogaine over other potential natural medicines.